Porous Fe/Cu Nanoreactor with Dual Insurance Design for Precision Chemotherapy and Chemodynamic Therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Targeted drug delivery and synergistic treatments are crucial for improving cancer therapy outcomes.
• Nanozymes offer potential for tumor chemodynamic therapy (CDT) by modulating the tumor microenvironment (TME).
• Integrating precise chemotherapy with CDT remains a significant challenge in cancer treatment.

Purpose of the Study:

• To develop a nanoreactor for targeted chemotherapy and CDT against melanoma.
• To create a system that utilizes dual targeting and responds to the acidic tumor microenvironment for controlled drug release.
• To enhance the efficacy of cancer treatment by combining the strengths of chemotherapy and nanozyme-based CDT.

Main Methods:

• A porous Fe/Cu bimetallic nanozyme carrier (FeCuNPs) was synthesized.
• The nanozyme carrier was co-loaded with a chemotherapeutic agent (IMB) and an anti-GD2 antibody (3F8).
• The resulting nanoreactor (3F8@FeCuNPs@IMB) was evaluated for its targeting, drug release, and therapeutic effects in vitro and in vivo.

Main Results:

• The nanoreactor demonstrated specific response to the acidic TME, enabling controlled release of the chemotherapeutic agent.
• The 3F8 antibody provided precise tumor targeting, minimizing off-target drug effects.
• FeCuNPs exhibited peroxidase-like and glutathione oxidase-like activity, enhancing CDT through hydroxyl radical generation and glutathione depletion.
• In vitro and in vivo studies confirmed the synergistic efficacy of the combined chemotherapy and CDT approach against melanoma.

Conclusions:

• The developed dual-insurance nanoreactor (3F8@FeCuNPs@IMB) effectively combines targeted chemotherapy and CDT.
• This approach offers a promising strategy for precise and effective treatment of melanoma.
• The study highlights the potential of nanozyme-based nanoreactors in advancing cancer therapy.